| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 22 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 22 days ago) | |
| US7169401 | EISAI INC | Topical skin care composition containing refined peanut oil |
Jul, 2023
(9 months ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
Belviq is owned by Eisai Inc.
Belviq contains Lorcaserin Hydrochloride.
Belviq has a total of 16 drug patents out of which 9 drug patents have expired.
Expired drug patents of Belviq are:
- US7977329
- US8207158
- US6953787
- US8273734
- US8575149
- US7514422
- US7169401
- US8367657
- US8546379
Belviq was authorised for market use on 27 June, 2012.
Belviq is available in tablet;oral dosage forms.
Belviq can be used as method for chronic weight management by decreasing food intake, method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition, use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment, method for chronic weight management by controlling weight gain, method for chronic weight management by treating obesity, method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd, method for chronic weight management.
Drug patent challenges can be filed against Belviq from 27 June, 2016.
The generics of Belviq are possible to be released after 07 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management by decreasing food intake; Method for chronic weight management by treating obesity; Method for chronic weight management by controlling weight gain; Method for ch...
Dosage: TABLET;ORAL
BELVIQ family patents
